ERs could be a new front in HIV prevention, tiny study suggests
NCT ID NCT04429971
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 25 times
Summary
This pilot study tested whether offering HIV prevention medication (PrEP) to high-risk patients in the emergency department is practical and acceptable. Twenty-six adults who were HIV-negative and medically stable were screened and given a starter pack of PrEP pills. The goal was to see if they would follow up with a PrEP provider within 30 days. The study aimed to overcome common barriers like lack of access to regular healthcare.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mount Sinai Beth Israel Hospital
New York, New York, 10003, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emtricitabine/tenofovir (PrEP medication)
What this could lead to
If successful, this approach could make it easier for people at high risk of HIV to start prevention medication without needing a separate doctor's visit.
What could go wrong
This was a very small pilot study with only 26 participants, so results may not apply broadly. It only tested feasibility, not whether PrEP actually prevents HIV in this setting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.